January 28, 2022 -- Septerna has launched with $100 million in series A financing. The financing will enable the company to advance its emerging pipeline of novel G protein-coupled receptor (GPCR)-targeted drug programs.
In addition, the company said it will continue to build its industrialized platform to enable drug discovery across the GPCR family and uncover novel mechanisms and new opportunities for previously difficult-to-drug GPCRs to address many diseases.
The company is creating broad new drug discovery opportunities across many disease areas for GPCRs. Septerna's proprietary native complex platform recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment, which enables industrial-scale drug discovery using novel screening technologies and structure-based drug design.
The series A financing was led by Third Rock Ventures, with significant support from Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital, and Logos Capital.